X4 Pharmaceuticals (XFOR) Property, Plant & Equipment (Net) Growth (3y) (2020 - 2026)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Property, Plant & Equipment (Net) Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 4.65% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 5.45% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 5.00% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -0.43% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 2.85% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 3.06% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 16.78% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | -1.81% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | -49.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -49.62% |
| Mar 31, 2026 | -47.10% |
| Dec 31, 2025 | -45.17% |
| Sep 30, 2025 | -43.27% |
| Jun 30, 2025 | -42.11% |
| Mar 31, 2025 | -29.72% |
| Dec 31, 2024 | -19.97% |
| Sep 30, 2024 | -20.50% |
| Jun 30, 2024 | -22.64% |
| Mar 31, 2024 | -25.41% |
| Dec 31, 2023 | -15.55% |
| Sep 30, 2023 | -16.67% |
| Jun 30, 2023 | 27.28% |
| Mar 31, 2023 | 27.56% |
| Dec 31, 2022 | 39.92% |
| Sep 30, 2022 | 50.83% |
| Jun 30, 2022 | 71.83% |
| Mar 31, 2022 | 72.99% |
| Dec 31, 2021 | 84.52% |
| Sep 30, 2021 | 71.60% |